Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Heron Therapeutics (HRTX) over the last 14 years, with Q2 2025 value amounting to $208000.0.

  • Heron Therapeutics' Capital Expenditures changed N/A to $208000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $955000.0, marking a year-over-year decrease of 4549.09%. This contributed to the annual value of $1.7 million for FY2024, which is 1042.07% up from last year.
  • According to the latest figures from Q2 2025, Heron Therapeutics' Capital Expenditures is $208000.0.
  • In the past 5 years, Heron Therapeutics' Capital Expenditures registered a high of $1.5 million during Q3 2021, and its lowest value of $45000.0 during Q3 2022.
  • Its 5-year average for Capital Expenditures is $486125.0, with a median of $356000.0 in 2021.
  • In the last 5 years, Heron Therapeutics' Capital Expenditures plummeted by 9706.07% in 2022 and then soared by 166222.22% in 2023.
  • Heron Therapeutics' Capital Expenditures (Quarter) stood at $390000.0 in 2021, then increased by 6.15% to $414000.0 in 2022, then crashed by 39.61% to $250000.0 in 2023, then soared by 155.2% to $638000.0 in 2024, then crashed by 67.4% to $208000.0 in 2025.
  • Its Capital Expenditures was $208000.0 in Q2 2025, compared to $109000.0 in Q1 2025 and $638000.0 in Q4 2024.